All Updates

All Updates

icon
Filter
Funding
Partnerships
PostEra raises USD 24 million Series A; secures USD 260 million AI deal with Pfizer
AI Drug Discovery
Jan 11, 2022
This week:
Funding
Pixxel secures USD 24 million in Series B funding to advance satellite constellation
Next-gen Satellites
Today
Regulation/policy
UK to make online retailers pay for e-waste recycling
Waste Recovery & Management Tech
Yesterday
Funding
Nexus W2V raises USD 140 million in equity funding to construct RNG facility
Waste Recovery & Management Tech
Yesterday
Partnerships
AgTechLogic partners with Birds Eye Aerial Drones to enhance sustainable farming with drone technology
Smart Farming
Yesterday
Product updates
Koch Agronomic Services launches Phosforce nutrient enhancer
Natural Fertilizers
Yesterday
Funding
Wald.ai raises USD 4 million in seed funding to expand operations
Generative AI Applications
Yesterday
Regulation/policy
Character AI faces lawsuit over teen safety violations
Generative AI Applications
Yesterday
Partnerships
Clarifai partners with Getty Images to offer AI-generated images for enterprise customers
Generative AI Applications
Yesterday
Product updates
OpenAI extends ChatGPT Canvas to free users
Generative AI Applications
Yesterday
M&A
Gen Digital to acquire MoneyLion for USD 1 billion to expand financial wellness offerings
Neobanks
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 11, 2022

PostEra raises USD 24 million Series A; secures USD 260 million AI deal with Pfizer

Funding
Partnerships

  • California-based AI drug discovery company PostEra has raised USD 24 million in a Series A funding round led by The Clermont Group, with participation from new investors Breyer Capital and Lifeforce Capital, and existing investors HOF Capital and Pioneer Fund, among others. 

  • The proceeds will be used to further develop its medicinal chemistry platform, establish its own drug discovery pipeline, and advance its collaborative drug discovery programs. 

<ul><li> Simultaneously, the company also extended its multi-year strategic partnership with Pfizer entered in December 2020 , to establish an AI lab. The lab will leverage Pfizer’s drug discovery expertise and data, together with PostEra’s AI technology, to work on a number of drug discovery programs across oncology and Covid-19.</ul>

  • As part of the renewed deal, PostEra will receive an upfront payment of USD 13 million, followed by up to USD 248 million in additional milestones and other tiered royalties.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.